We and others have reported the associations of PBRM1, SETD2, BAP1, and KDM5C mutations with advanced stage, grade, and tumor invasiveness [20, 21], and discovered that SETD2 and BAP1 mutations are associated with lower cancer-specific survival rates [21, 22]. The gene discussed is SETD2; the disease is neoplasm.